reference scaled bioequivalence [RSABE / ABEL]

posted by AngusMcLean – USA, 2010-11-07 15:55 (5346 d 18:56 ago) – Posting: # 6111
Views: 16,135

Sunday November 7, 201:

I discovered this slide from a presentation from Pharsight

From: 80-125% to ± 1.25σ(Ref)/0.25I understand it is an interpretation of the direction of FDA thinking relating to extending the criteria for means ratio and confidence intervals for BE of highly variable drugs.;-)

The observed ratio must be within 80-125%; the study design must be partially or fully replicated.

What do you think of it?

Angus


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,688 registered users;
50 visitors (0 registered, 50 guests [including 8 identified bots]).
Forum time: 11:52 CEST (Europe/Vienna)

Complex, statistically improbable things are by their nature
more difficult to explain than
simple, statistically probable things.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5